Based on a plethora of pre-clinical studies, and close analogy to imatinib in CML (i.e., a driver kinase inhibitor therapy in a chronic myeloid neoplasm), MPN patients were seemingly primed to be successfully treated by JAK2 inhibitors. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.